흑색종 | 바이오모아

AntibodystaleWashington University School of…Phase 1

Relatilmab (Relatilmab)

Advanced Melanoma; Metastatic Melanoma · Advanced Melanoma

#AdvancedMelanoma#Antibody#Phase1#항체#면역항체+3

AntibodystaleNektar TherapeuticsPhase 2

nivolumab (Opdivo, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab)

Melanoma; Renal Cell Carcinoma · HER2

#HER2#Antibody#Phase2#항체#면역항체+4

효능 ORR 64%임상시험 1상태 ACTIVE

CGTBiologicstaleUniversity of PennsylvaniaPhase 1

T cells modified with RNA anti -cMET CAR (T cells modified with RNA anti -cMET CAR)

Malignant Melanoma; Breast Cancer · Malignant Melanoma

#MalignantMelanoma#CGT#Phase1#세포유전치료#CAR-T+3

CGTBiologicstaleNantes University HospitalPhase 2

nivolumab (Opdivo, TIL + IL-2 + Nivolumab)

Melanoma · Melanoma

#Melanoma#CGT#Phase2#세포유전치료#CAR-T+2

AntibodystaleChia Tai Tianqing Pharmaceutica…Phase 2

TQB2922 injection+TAS-102 tablets ± Bevacizumab (TQB2922 injection+TAS-102 tablets ± Bevacizumab)

RAS/BRAF Wild Type Colorectal Cancer · RAS/BRAF Wild Type Colorectal Cancer

#RASBRAFWildTypeColorectalCancer#Antibody#Phase2#항체#면역항체+4

AntibodystaleImmunocore LtdPhase 3

pembrolizumab (Keytruda, Tebentafusp with Pembrolizumab)

Advanced Melanoma · Advanced Melanoma

#AdvancedMelanoma#Antibody#Phase3#항체#면역항체+2

AntibodystaleXencor, Inc.Phase 1

XmAb®22841 (XmAb®22841)

Melanoma; Cervical Carcinoma · Melanoma

#Melanoma#Antibody#Phase1#항체#면역항체+3

AntibodystaleXencor, Inc.Phase 1

XmAb®23104 (XmAb®23104)

Melanoma (Excluding Uveal Melanoma); Cervical Carcinoma · HER2

#HER2#Antibody#Phase1#항체#면역항체+4

AntibodystaleXencor, Inc.Phase 1

XmAb®808 (XmAb®808)

Head and Neck Squamous Cell Carcinoma; Melanoma Excluding Uveal Melanoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase1#항체#면역항체+3

AntibodystaleBristol Myers SquibbPhase 1

ipilimumab (Yervoy®, Yervoy® (ipilimumab))

Melanoma (Excluding Uveal Melanoma); Cervical Carcinoma · HER2

#HER2#Antibody#Phase1#항체#면역항체+4

AntibodystaleNational Cancer Institute (NCI)Phase 1

aflibercept (Eylea, VEGF Trap-Eye, Eylea HD, Ziv-Aflibercept)

Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Colorectal Carcinoma · FRα

#FR#Antibody#Phase1#항체#면역항체+4

CGTBiologicstaleNational Cancer Institute (NCI)Phase 2

anti-gp100:154-162 Tcell receptor (TCR, anti-gp100:154-162 Tcell receptor, anti-gp100:154-162 Tcell receptor (TCR) peripheral blood lymphocyte (PBL))

Metastatic Melanoma; Skin Cancer · Metastatic Melanoma

#MetastaticMelanoma#CGT#Phase2#세포유전치료#CAR-T+3

CGTBiologicstaleNational Institutes of Health C…Phase 2

anti-p53 T-cell receptor-transduced peripheral blood lymphocytes (anti-p53 T-cell receptor-transduced peripheral blood lymphocytes)

Kidney Cancer; Melanoma (Skin) · Kidney Cancer

#KidneyCancer#CGT#Phase2#세포유전치료#CAR-T+3

CGTBiologicstaleNational Cancer Institute (NCI)Phase 2

autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes (autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes)

Melanoma; Skin Cancer · Melanoma

#Melanoma#CGT#Phase2#세포유전치료#CAR-T+3

CGTBiologicstaleNational Cancer Institute (NCI)Phase 2

autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes (autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes)

Skin Cancer; Melanoma · Skin Cancer

#SkinCancer#CGT#Phase2#세포유전치료#CAR-T+3

CGTBiologicstaleNational Cancer Institute (NCI)Phase 2

autologous anti-gp 100:154-162 T-cell receptor gene-engineered tumor infiltrating lymphocytes (autologous anti-gp 100:154-162 T-cell receptor gene-engineered tumor infiltrating lymphocytes)

Skin Cancer; Melanoma · Skin Cancer

#SkinCancer#CGT#Phase2#세포유전치료#CAR-T+3